On evaluating RFS and OS of the BC groups, elevation in circulating IGFBP-2 and PAPP-A quantities in the serum, determined at start of treatment, was found to be independently associated with worse prognosis in females with long-term follow up subsequent to treatment. This evidence concerns the gene PAPPA and breast cancer.